Hansa Biopharma — Juni 2024
-
Hansa Biopharma sidst i denne korte video: https://proinvestor.com/boards/121002
-
Sarepta Therapeutics Announces Expanded US FDA Approval of ELEVIDYS to Duchenne Muscular Dystrophy Patients Ages 4 and Above
-
-
Godmorgen
-
Kursudviklingen for Sarepta Therapeutics efter børstid kommer ikke til at blive afspejlet direkte, da DMD-aftalen kun udgør en mindre del/værdi af Hansa Biopharmas portefølje, som eksempelvis nævnt i en tidligere analyse fra Penser Access (nu overtaget af Carnegie).
-
Sarepta Therapeutics surges 36% after-hours following expanded FDA approval
-
Det bliver spændende.
-
Sarepta's DMD gene therapy secures much-sought-after label expansion https://firstwordpharma.com/story/5868924
-
Sarepta Catapults 30% After Hitting A 'Grand Slam' Approval In Muscular Dystrophy
Sarepta Catapults 30% After Hitting A 'Grand Slam' Approval
Sarepta stock rocketed Friday after hitting a "grand slam" approval that expands the market for its Duchenne muscular dystrophy gene therapy.
Investor's Business Daily (www.investors.com)
"The approval expands the market for Elevidys by more than tenfold, Leerink Partners analyst Joseph Schwartz said. Under the original approval, about 7% of patients were eligible for the gene therapy. Now, about 80% are eligible, he said in a report."
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind